Loading...
Since 1990, several different treatment regimens have been found to reduce the number and severity of relapses in patients with relapsing/remitting and secondary-progressive multiple sclerosis (MS). Previous cost-effectiveness analyses of these therapies have produced results ranging from cost savings to costs of more than US$1.5 million per quality-adjusted life-year (QALY). These British investigators undertook another analysis to correct for suspected flaws in modeling MS clinical courses.
Data were collected from multiple U.K. databases. Six regimens, including 5 different interferon-β regimens and 1 glatiramer regimen, were evaluated; cost-effectiveness for 20 years was calculated. The base cost per QALY, using any of the regimens, rang…